91 related articles for article (PubMed ID: 8681301)
1. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma.
Rothenberg ML; Abbruzzese JL; Moore M; Portenoy RK; Robertson JM; Wanebo HJ
Cancer; 1996 Aug; 78(3 Suppl):627-32. PubMed ID: 8681301
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of therapeutic effect of chemotherapy with reference to clinical benefit response].
Okada S
Gan To Kagaku Ryoho; 2000 May; 27(5):696-701. PubMed ID: 10832437
[TBL] [Abstract][Full Text] [Related]
3. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
4. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
5. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer.
Hochster HS; Haller DG; de Gramont A; Berlin JD; Philip PA; Moore MJ; Ajani JA
Cancer; 2006 Aug; 107(4):676-85. PubMed ID: 16847885
[TBL] [Abstract][Full Text] [Related]
6. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization.
Homma H; Doi T; Mezawa S; Takada K; Kukitsu T; Oku T; Akiyama T; Kusakabe T; Miyanishi K; Niitsu Y
Cancer; 2000 Jul; 89(2):303-13. PubMed ID: 10918160
[TBL] [Abstract][Full Text] [Related]
7. The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure.
Ducreux M; Boige V; Goéré D; Deutsch E; Ezra P; Elias D; Malka D
Best Pract Res Clin Gastroenterol; 2007; 21(6):997-1014. PubMed ID: 18070700
[TBL] [Abstract][Full Text] [Related]
8. Modern management of pancreatic carcinoma.
Goldstein D; Carroll S; Apte M; Keogh G
Intern Med J; 2004 Aug; 34(8):475-81. PubMed ID: 15317546
[TBL] [Abstract][Full Text] [Related]
9. Early clinical experience using high intensity focused ultrasound for palliation of inoperable pancreatic cancer.
Xiong LL; Hwang JH; Huang XB; Yao SS; He CJ; Ge XH; Ge HY; Wang XF
JOP; 2009 Mar; 10(2):123-9. PubMed ID: 19287104
[TBL] [Abstract][Full Text] [Related]
10. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer: progress in cancer therapy.
Pierantoni C; Pagliacci A; Scartozzi M; Berardi R; Bianconi M; Cascinu S
Crit Rev Oncol Hematol; 2008 Jul; 67(1):27-38. PubMed ID: 18356073
[TBL] [Abstract][Full Text] [Related]
12. Endpoints for assessing drug activity in clinical trials.
Pazdur R
Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
[TBL] [Abstract][Full Text] [Related]
13. Research trends in the treatment of neoplasms of the exocrine pancreas.
Cellini N; Morganti AG; Luzi S; Macchia G; Smaniotto D; Trodella L
Rays; 2000; 25(3):375-7. PubMed ID: 11367905
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials.
Cubiella J; Castells A; Fondevila C; Sans M; Sabater L; Navarro S; Fernández-Cruz L
Am J Gastroenterol; 1999 May; 94(5):1271-8. PubMed ID: 10235206
[TBL] [Abstract][Full Text] [Related]
15. Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials.
Schwartz LH; Mazumdar M; Wang L; Smith A; Marion S; Panicek DM; Motzer RJ
Cancer; 2003 Oct; 98(8):1611-9. PubMed ID: 14534876
[TBL] [Abstract][Full Text] [Related]
16. Old and new drugs in systemic therapy of pancreatic cancer.
Pasetto LM; Jirillo A; Stefani M; Monfardini S
Crit Rev Oncol Hematol; 2004 Feb; 49(2):135-51. PubMed ID: 15012974
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
18. Nonsurgical management of malignant thymoma.
Hejna M; Haberl I; Raderer M
Cancer; 1999 May; 85(9):1871-84. PubMed ID: 10223225
[TBL] [Abstract][Full Text] [Related]
19. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
20. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
